CGP-56697

Known as: CGP 56697 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-1999
02419971999

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
In India, treatment of acute, uncomplicated Plasmodium falciparum malaria is becoming increasingly difficult due to resistance to… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The new oral fixed combination artemether-lumefantrine (CGP 56697) has proved to be an effective and well-tolerated treatment of… (More)
Is this relevant?
1999
1999
CGP 56697, a new oral fixed combination of artemether and benflumetol, was tested in a double-blinded, randomized trial in 252… (More)
Is this relevant?
1999
1999
The pharmacokinetics of benflumetol as a fixed combination, artemether-benflumetol (CGP 56697), following three regimens [regimen… (More)
Is this relevant?
1999
1999
CGP 56697 (Riamet) is a new oral anti-malarial drug composed of artemether and lumefantrine (benflumetol) which combines the fast… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
AIMS To investigate the pharmacokinetic and pharmacodynamic properties of artemether and benflumetol in a fixed combination… (More)
Is this relevant?
1998
1998
A randomized, open trial involving 260 Tanzanian children, aged 1-5 years, with acute Plasmodium falciparum malaria was conducted… (More)
Is this relevant?
1998
1998
OBJECTIVE To test the efficacy of a new compound drug (CGP 56697) against acute, uncomplicated falciparum malaria. METHOD… (More)
Is this relevant?
1997
1997
New antimalarial drugs are urgently needed. The use of short courses of the new antimalarial drug artemether as monotherapy has… (More)
Is this relevant?
1997
1997
One hundred and two Chinese out-patients with naturally acquired, previously untreated, falciparum malaria were selected to… (More)
Is this relevant?